Commentary on the role of treatment-related HIV compensatory mutations on increasing virulence: New discoveries twenty years since the clinical testing of protease inhibitors to block HIV-1 replication

BMC Medicine

Volumn 10, Issue , 2012, Pages

  Arts, Eric J ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral drugs; CD4 cell counts; drug resistance; fitness; human immunodeficiency virus; protease inhibitors; viral load; virulence

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL RESISTANCE; CD4 LYMPHOCYTE COUNT; DISEASE COURSE; GENETIC POLYMORPHISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NOTE; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION; VIRUS VIRULENCE;

CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTATION, MISSENSE; VIRAL LOAD; VIRULENCE;

EID: 84866872409     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-10-114     Document Type: Note

References (18)

1. Brun-Vezinet F, Boucher C, Loveday C, Descamps D, Fauveau V, Izopet J, Jeffries D, Kaye S, Krzyanowski C, Nunn A, Schuurman R, Seigneurin JM, Tamalet C, Tedder R, Weber J, Weverling GJ. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee. Lancet 1997, 350:983-990. 10.1016/S0140-6736(97)03380-1, 9329513.
2. Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, Henry WK, Lederman MM, Phair JP, Niu M, Hirsch MS, Merigan TC. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med 1996, 335:1081-1090. 10.1056/NEJM199610103351501, 8813038.
3. Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdes JM, Henry D, Sattler F, La MA, Leonard JM, Ho D. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995, 333:1534-1539.
4. Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F, Gonzales J, Raventos A, Rubio R, Bouza E, Pintado V, Aguado AG, de Lomas JG, Delgado R, Borleffs JCC, Hsu A, Valdes JM, Boucher CAB, Cooper DA. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med 1995, 333:1528-1533. 10.1056/NEJM199512073332303, 7477167.
5. Wainberg MA, Salomon H, Gu Z, Montaner JS, Cooley TP, McCaffrey R, Ruedy J, Hirst HM, Cammack N, Cameron J, Nicholson W. Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS 1995, 9:351-357.
6. Richman DD, Havlir D, Corbeil J, Looney D, Ignacio C, Spector SA, Sullivan J, Cheeseman S, Barringer K, Pauletti D. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994, 68:1660-1666. 236624, 7509000.
7. Arts EJ, Hazuda DJ. HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med 2012, 2:a007161. 3312400, 22474613.
8. Theys K, Deforche K, Vercauteren J, Libin P, van de Vijver DAMC, Albert J, Asjo B, Balotta C, Bruckova M, Camacho RJ, Clotet B, Coughlan S, Grossman Z, Hamouda O, Horban A, Korn K, Kostrikis LG, Kucherer C, Nielsen C, Paraskevis D, Poljak M, Puchhammer-Stockl E, Riva C, Ruiz L, Liitsola K, Schmit J, Schuurman R, Sonnerborg A, Stanekova D, Stanojevic M, et al. Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients. Retrovirology 2012, 9:81. 10.1186/1742-4690-9-81, 23031662.
9. Croteau G, Doyon L, Thibeault D, McKercher G, Pilote L, Lamarre D. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J Virol 1997, 71:1089-1096. 191160, 8995629.
10. Nijhuis M, Schuurman R, de Jong D, Erickson J, Gustchina E, Albert J, Schipper P, Gulnik S, Boucher CA. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 1999, 13:2349-2359. 10.1097/00002030-199912030-00006, 10597776.
11. Weber J, Rangel HR, Chakraborty B, Marotta ML, Valdez H, Fransen K, Florence E, Connick E, Smith KY, Colebunders RL, Landay A, Kuritzkes DR, Lederman MM, Vanham G, Quinones-Mateu ME. Role of Baseline pol Genotype in HIV-1 Fitness Evolution. J Acquir Immune Defic Syndr 2003, 33:448-460. 10.1097/00126334-200308010-00005, 12869833.
12. Arien KK, Vanham G, Arts EJ. Is HIV-1 evolving to a less virulent form in humans?. Nat Rev Microbiol 2007, 5:141-151. 10.1038/nrmicro1594, 17203103.
13. Tebit DM, Arts EJ. Tracking a century of global expansion and evolution of HIV to drive understanding and to combat disease. Lancet Infect Dis 2011, 11:45-56. 10.1016/S1473-3099(10)70186-9, 21126914.
14. Deforche K, Camacho R, Van LK, Lemey P, Rambaut A, Moreau Y, Vandamme AM. Estimation of an in vivo fitness landscape experienced by HIV-1 under drug selective pressure useful for prediction of drug resistance evolution during treatment. Bioinformatics 2008, 24:34-41. 10.1093/bioinformatics/btm540, 18024973.
15. Troyer RM, McNevin J, Liu Y, Zhang SC, Krizan RW, Abraha A, Tebit DM, Zhao H, Avila S, Lobritz MA, McElrath MJ, Le GS, Mullins JI, Arts EJ. Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog 2009, 5:e1000365. 10.1371/journal.ppat.1000365, 2659432, 19343217.
16. Iglesias-Ussel MD, Casado C, Yuste E, Olivares I, Lopez-Galindez C. In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variants. J Gen Virol 2002, 83:93-101.
17. Tebit DM, Lobritz M, Lalonde M, Immonen T, Singh K, Sarafianos S, Herchenroder O, Krausslich HG, Arts EJ. Divergent evolution in reverse transcriptase (RT) of HIV-1 group O and M lineages: impact on structure, fitness, and sensitivity to nonnucleoside RT inhibitors. J Virol 2010, 84:9817-9830. 10.1128/JVI.00991-10, 2937803, 20631150.
18. Anastassopoulou CG, Marozsan AJ, Matet A, Snyder AD, Arts EJ, Kuhmann SE, Moore JP. Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss. PLoS Pathog 2007, 3:e79. 10.1371/journal.ppat.0030079, 1885273, 17542646.